Catalog No.
Product Name
Application
Product Information
Citations
-
TLR3 Inhibitor
CU-CPT 4a is a selective inhibitor of TLR3 signaling, effectively blocking the downstream pathways activated by the TLR3/dsRNA complex. This compound suppresses the production of pro-inflammatory cytokines, including TNF-α and IL-1β, making it a valuable tool for research into immune responses and inflammation. CU-CPT 4a is suitable for studies focused on modulating TLR3-related signaling pathways in various disease models. -
SARM1 Activator/CD38 Inhibitor
Sulfo-ara-F-NMN is a selective SARM1 activator and CD38 inhibitor, functioning as a mimetic of nicotinamide mononucleotide (NMN). It effectively activates SARM1 while inhibiting CD38, with an IC50 of approximately 10 μM. This compound is valuable for research applications focused on the modulation of intracellular cyclic ADP-ribose (cADPR) production and the exploration of pathways involving SARM1 and CD38 in cellular signaling. -
TLR7 Agonist
Imiquimod hydrochloride is a selective TLR7 agonist that serves as an immune response modifier. It demonstrates notable antiviral and antitumor properties in vivo, making it a valuable tool for studying various conditions. Research applications include exploration of treatments for external genital and perianal warts, cancer therapies, and potential therapeutic approaches for COVID-19. -
TLR2 Agonist
Zymosan A is a TLR2 agonist derived from Saccharomyces cerevisiae, known for its ability to activate Toll-like receptor 2. It demonstrates significant radioprotective effects, effectively mitigating ionizing radiation-induced intestinal injuries in murine models. Additionally, Zymosan A supports the regeneration of intestinal stem cells following radiation exposure, making it a valuable tool for research in intestinal health and radioprotection. -
TLR9 Ligand
ODN 2216 is a selective agonist for human Toll-like receptor 9 (TLR9), known for its role in immune modulation. It stimulates the production of large quantities of interferons, specifically IFN-α and IFN-β, through activation of plasmacytoid dendritic cells (pDCs). ODN 2216 also enhances IL-12 (p40) production by dendritic cells and promotes interferon-gamma (IFN-γ) secretion in peripheral blood mononuclear cells (PBMC) in an indirect manner mediated by IFN-α/β. Additionally, this reagent activates natural killer (NK) cells and supports IFN-γ production in TCR-activated CD4+ T cells, making it valuable for research in immunology and vaccine development. -
TLR Antagonist
ODN TTAGGG is a TLR9, AIM2, and cGAS antagonist that functions as an inhibitory oligonucleotide. This compound inhibits the activation of the AIM2 inflammasome as well as cGAS by competing with endogenous DNA. As a result, ODN TTAGGG obstructs AIM2-mediated pyroptosis and reduces IL-18 production. Its immunosuppressive properties make it useful in research related to autoimmune diseases, including lupus erythematosus. -
TLR7/TLR9 Inhibitor
AT791 is a potent inhibitor of Toll-like receptors 7 and 9 (TLR7/TLR9), demonstrating strong oral bioavailability. This compound effectively blocks TLR7 and TLR9 signaling pathways in a range of human and murine cell types, as well as inhibiting DNA-TLR9 interactions in vitro. AT791 is applicable in research focused on immune modulation and the characterization of TLR-mediated signaling. -
TLR3/7/9 Inhibitor
ODN 2088 is a potent inhibitor of Toll-like receptors 3, 7, and 9 (TLR3, TLR7, TLR9), demonstrating a strong capacity to modulate immune responses. This compound effectively suppresses the release of key pro-inflammatory cytokines, including interferon-alpha (IFN-α) and interleukin-6 (IL-6), without exhibiting cytotoxic effects. ODN 2088 is valuable for research applications focused on understanding TLR-mediated signaling pathways and their roles in various immune-related conditions. -
TLR2/TLR4 Antagonist
Sparstolonin B is a selective antagonist of Toll-like receptors 2 and 4 (TLR2/TLR4), effectively inhibiting TLR2- and TLR4-mediated inflammatory signaling pathways. This compound demonstrates notable anti-HIV and anticancer properties, making it valuable for research into immune modulation and cancer therapy. Its ability to block key inflammatory responses adds significance to its use in studying various diseases linked to TLR signaling. -
TLR9 Agonist
ODN 2395 is a C class oligodeoxynucleotide that functions as a TLR9 agonist, promoting immune responses. Its primary application is as a vaccine adjuvant, enhancing the efficacy of immunological vaccines. This compound facilitates the activation of dendritic cells and B cells, thereby driving robust adaptive immunity. Sequence: 5'-tcgtcgttttcggcgc:gcgccg-3'. -
TLR9 Agonist
ODN 1018 is a Toll-like receptor 9 (TLR9) agonist functioning as an immune modulator. It demonstrates adjuvant activity by enhancing CD8+ T cell responses when combined with liposomal nanoparticles encapsulating ovalbumin (OVA) peptides. Additionally, ODN 1018 effectively induces prolonged suppression of allergic airway inflammation, making it a valuable tool for research into allergic asthma and systemic lupus erythematosus. -
Toll-like Receptor (TLR) Inhibitor
Okanin is a potent Toll-like Receptor (TLR) inhibitor derived from the flowering plant Coreopsis tinctoria. It exhibits significant biological activity by attenuating lipopolysaccharide (LPS)-induced microglial activation via the inhibition of the TLR4/NF-κB signaling pathway. This compound is useful for research applications focusing on neuroinflammation and the modulation of immune responses in microglial cells. -
TLR7/8 Inhibitor
Enpatoran hydrochloride is a dual inhibitor of Toll-like receptors 7 and 8, demonstrating potent activity with IC50 values of 11.1 nM and 24.1 nM, respectively, in HEK293 cells. This compound is selectively inactive against TLR3, TLR4, and TLR9, effectively blocking both synthetic and natural RNA ligands. Enpatoran hydrochloride exhibits favorable pharmacokinetic profile in vivo, making it a valuable tool for research into innate and adaptive autoimmunity pathways. -
TLR7/8 Agonist
CL097 is a potent agonist of Toll-like receptors 7 and 8 (TLR7/8), eliciting a robust pro-inflammatory cytokine response in macrophages. By priming NADPH oxidase, CL097 enhances fMLF-stimulated reactive oxygen species (ROS) production. This compound is valuable for research applications in immunology and inflammation studies, particularly in understanding innate immune responses. -
TLR9 Inhibitor
TLR9-IN-1 is a potent and selective inhibitor of Toll-like receptor 9 (TLR9), exhibiting an IC50 value of 7 nM for human TLR9. This compound is valuable for studying diseases linked to aberrant immune responses, making it an important tool in immunological research and therapeutic development. Researchers can utilize TLR9-IN-1 to explore the modulation of TLR9 pathways in various inflammatory and autoimmune conditions. -
TLR8 Agonist
Selgantolimod is a potent and selective agonist of toll-like receptor 8 (TLR8). This orally active compound has demonstrated significant biological activity in activating the immune response, making it a valuable agent in the treatment of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections. Its mechanism of action supports research into immunotherapeutic strategies targeting viral pathogens. -
TLR7/8 Agonist
Gardiquimod is an imidazoline compound that acts as an agonist for Toll-like receptors 7 and 8 (TLR7/8). This reagent has been shown to inhibit HIV-1 infection in macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod specifically activates TLR7 at concentrations below 10 μM, making it a valuable tool in immunological research and studies related to viral infections. -
TLR8 Agonist
TL8-506 is a selective TLR8 agonist with an EC50 of 30 nM. This compound exhibits immunomodulatory properties, making it a valuable tool for investigating therapeutic approaches in tuberculosis and cancer immunotherapy. Researchers can leverage TL8-506 to enhance immune responses and study the underlying mechanisms of TLR8-mediated signaling. -
TLR-9 Agonist
ODN 1668 is a TLR-9 agonist classified as a class B CpG oligodeoxynucleotide (ODN). This reagent exhibits significant immune regulatory properties, enhancing IgG2 antibody levels and promoting T cell and B cell immune responses, making it useful in vaccine adjuvant research. Additionally, ODN 1668 induces an antimicrobial immune response through a CaTLR9-dependent pathway in groupers. Sequence: 5'-tccatgacgttcctgatgct-3’. -
Toll-like Receptor (TLR) Agonist
TLR7/8 Agonist 1 is a dual agonist of Toll-like Receptors 7 and 8, belonging to the imidazoquinoline class. This compound activates the innate immune response by engaging TLR7 and TLR8, leading to the production of pro-inflammatory cytokines. It has significant applications in immunological research, particularly in studies related to viral infections, cancer immunotherapy, and the modulation of immune responses. -
TLR7/TLR8 Inhibitor
TLR7/8-IN-1 is a potent inhibitor of Toll-like receptors 7 and 8, which play critical roles in the immune response. This compound exhibits strong potential in modulating inflammatory pathways associated with autoimmune diseases. It serves as a valuable tool for researchers investigating the therapeutic targeting of TLR7 and TLR8 in various immunological studies. -
Toll-like Receptor (TLR) Agonist
Neoseptin 3 is an agonist of Toll-like receptor 4 (TLR4) and myeloid differentiation factor 2 (MD-2), exhibiting an EC50 of 18.5 μM. This compound promotes innate immune responses and enhances cytokine production, making it a valuable tool for studying immune system activation. Neoseptin 3 is suitable for research on inflammatory diseases and immune modulation. -
TLR8 Agonist
CL075 is a selective TLR8 agonist that activates the MyD88-dependent signaling pathway, leading to the production of inflammatory cytokines and type I interferons (IFNs). This compound enhances NF-κB and IRF7 activation, contributing to immune modulation. It is primarily used in research applications focused on inflammation and immune response mechanisms. -
TLR3 Ligand
Polyinosinic acid sodium is the sodium salt of polyinosinic acid, a single-stranded homonucleic acid that serves as a Toll-like Receptor 3 (TLR3) ligand. By activating TLR3, polyinosinic acid sodium enhances the cellular immune response through the TRIF signaling pathway. This reagent shows potential for use in studies focused on immune regulation and adjuvant therapies in various research applications. -
TLR4 Inhibitor/PROTAC Linker
TLR4-IN-C34-C2-COOH is a TLR4 inhibitor that serves as a PROTAC linker. It demonstrates significant potential in the modulation of inflammatory responses, particularly in studies involving acute myocardial injury. By targeting TLR4 in enterocytes and macrophages, TLR4-IN-C34-C2-COOH effectively reduces systemic inflammation in murine models of endotoxemia and necrotizing enterocolitis, making it a valuable tool for research in inflammation-related pathways. -
TLR 7 Agonist
Loxoribine, a guanosine analog, functions as a selective Toll-like receptor (TLR) 7 agonist. This compound exhibits significant anti-viral and anti-tumor activities, making it valuable for research applications in immunotherapy and cancer treatment. Its oral bioavailability expands its potential for in vivo studies. -
TLR7 Agonist
DSR-6434 is a highly potent and selective agonist of Toll-like receptor 7 (TLR7), exhibiting EC50 values of 7.2 nM for human TLR7 and 4.6 nM for mouse TLR7. This compound demonstrates significant antitumor activity, making it a valuable tool for studying cancer immunotherapy and TLR7 signaling pathways in various research applications. -
TLR7 Agonist
CL264 is a selective agonist of Toll-like receptor 7 (TLR7), primarily utilized for examining innate immune signaling pathways. This compound enhances the activation of immune responses through TLR7 stimulation, making it a valuable tool for research in immunology and inflammation. Its application extends to understanding the mechanisms of antiviral responses and potential therapeutic strategies targeting TLR-mediated immune modulation. -
Toll-like Receptor (TLR) Antagonist
TLR7/8/9-IN-1 is a potent small molecule antagonist targeting Toll-like receptors 7, 8, and 9, with an IC50 value of 43 nM. This compound effectively inhibits TLR-mediated signaling pathways, playing a crucial role in the immune response. It is valuable for research applications focused on inflammatory diseases, autoimmune disorders, and the modulation of innate immunity. -
TLR9 Agonist
CpG ODN 10101 is a TLR9 agonist, designed as a synthetic oligodeoxynucleotide modified with phosphate thioester. This compound activates B cells and plasmacytoid dendritic cells, leading to enhanced production of cytokines and chemokines, including interferon-α and IP-10. By modulating innate immunity and promoting Th1 adaptive responses, CpG ODN 10101 demonstrates antiviral properties and enhances vaccine immunogenicity, highlighting its potential as an immunomodulator and vaccine adjuvant in the development of therapies for chronic hepatitis C and various infectious diseases. -
TLR4 Antagonist
CAY10614 is a potent TLR4 antagonist that inhibits lipid A-induced activation of the TLR4 receptor, exhibiting an IC50 of 1.675 μM. This compound has demonstrated the ability to improve survival rates in mouse models of lethal endotoxin shock. CAY10614 is valuable for research applications investigating TLR4-mediated inflammatory responses and the development of therapeutic strategies targeting sepsis and other endotoxin-related conditions. -
TLR9 Antagonist
CPG-52364 is a TLR9 antagonist that exhibits inhibitory activity against TLR9 in the HEK293-hTLR9 cell line, with an IC50 value of 4.6 nM. This compound is valuable for research applications investigating immune response modulation, particularly in studies related to autoimmune diseases and inflammation. Its specificity for TLR9 makes it a useful tool for exploring the therapeutic potential of TLR modulation in various biological contexts. -
TLR7/8 Agonist
CL097 hydrochloride is a potent agonist of Toll-like receptors 7 and 8 (TLR7/8) that activates pro-inflammatory cytokine production in macrophages. This compound also facilitates NADPH oxidase priming, leading to enhanced reactive oxygen species (ROS) generation upon fMLF stimulation. CL097 is valuable in research applications related to immune response and inflammation. -
Anti-inflammatory Agent
Tiopropamine is an anti-inflammatory agent primarily targeting histamine receptors. It exhibits significant potential in modulating inflammatory responses, making it a valuable tool for studying various inflammatory conditions. Its ability to influence histamine activity facilitates research into novel therapeutic strategies for related diseases. -
Anti-inflammatory Agent
Pibaxizine is an orally active anti-inflammatory agent that functions as a histamine receptor antagonist. It effectively mitigates bronchoconstriction induced by histamine, making it a valuable tool for studies related to inflammation and immunology. Pibaxizine is particularly relevant in research focused on respiratory conditions, including asthma, where it can aid in understanding inflammatory pathways and potential therapeutic interventions. -
Anti-inflammatory Agent
Dimephosphon is an anti-inflammatory agent that exhibits antihistamine and antiserotonin activity. It is effective in preserving spinal cord conduction and decreasing the excitability of spinal motor neurons near lesions. Additionally, Dimephosphon activates lymphatic vessel movement, thereby enhancing lymphatic circulation. This compound is useful in research focused on inflammatory edema, acute spinal cord injury, and lymphatic circulation disorders. -
Anti-Inflammatory Agent
Cicloprofen is a non-steroidal anti-inflammatory drug (NSAID) that primarily targets cyclooxygenase (COX) enzymes, inhibiting prostaglandin synthesis. This compound demonstrates significant anti-inflammatory and analgesic activities, making it effective for alleviating pain and inflammation in various conditions. Its applications in biochemical research include studies on pain pathways and the mechanism of action of NSAIDs in inflammation management. -
Inflammatory Cell Activation Inhibitor
CI-959 is an inhibitor of inflammatory cell activation, primarily targeting signaling pathways involved in immune response modulation. It demonstrates significant anti-inflammatory and anti-allergic properties by reducing the production of reactive oxygen species in neutrophils, inhibiting neutrophil adhesion, and blocking histamine release from mast cells. CI-959 also effectively suppresses the release of inflammatory mediators, including histamine, leukotrienes, and thromboxane, from guinea pig and human lung tissues. This compound is valuable for research focused on inflammatory and allergic diseases, particularly asthma. -
Anti-Inflammatory Agent/Anti-Tumor Agent
AHR-1911 is a thiourea derivative characterized by its anti-inflammatory and anti-tumor properties, primarily functioning through inhibition of protein synthesis. This compound demonstrates potential in enhancing healing in burned skin and exhibits histamine-like effects upon intradermal administration. Research has shown that AHR-1911 can effectively inhibit tumor growth and may also lower arterial pressure in certain animal models, making it valuable for investigations into inflammation and oncology. -
Target Protein Ligand
3-Fluoro-desmethyl-cabozantinib is a selective ligand for the BCL6 protein, facilitating targeted protein degradation through PROTAC technology. It serves as an essential building block in the development of innovative therapeutics aimed at modulating protein levels for various cancer applications. This compound may enhance research into BCL6-related pathways and assist in the design of more effective treatments. -
BTK/IKZF1/3 PROTAC Ligand
BTK/IKZF1/3 ligand 1 is a PROTAC ligand targeting Bruton's tyrosine kinase (BTK) and the Ikaros family zinc finger proteins (IKZF1/3). This compound can be conjugated with E3 ligase ligands and linkers to produce PROTAC BTK/IKZF1/3 Degrader-1, facilitating targeted protein degradation. It is valuable for cancer research, supporting investigations into therapeutic strategies aimed at modulating BTK and IKZF1/3 activity in malignant cells. -
BTK/IKZF1/3 PROTAC Degrader
PROTAC BTK/IKZF1/3 Degrader-1 is a selective and orally bioavailable degrader targeting BTK, IKZF1, and IKZF3 through the PROTAC mechanism. This compound exhibits significant antitumor activity, making it a valuable tool for cancer research, particularly in the context of lymphoma. Its unique mechanism of action allows for the targeted degradation of specific oncogenic proteins, facilitating studies in therapeutic strategies and disease mechanisms. -
Nrf1/Nrf2 Activator
Rosolutamide is a potent Nrf1 and Nrf2 activator that enhances the expression of proteasome subunits, antioxidant enzymes, and molecular chaperones through the activation of these transcription factors. This curcumin analog facilitates the degradation of polyglutamine (polyQ) androgen receptors via the ubiquitin-proteasome pathway, thereby improving motor function in mouse models of spinal and bulbar muscular atrophy (SBMA). Additionally, Rosolutamide promotes mitochondrial function, autophagy, and reduces intracellular and mitochondrial reactive oxygen species (ROS) levels, making it a valuable tool for research exploring neurodegenerative diseases and oxidative stress. -
FKBP51-Hsp90 Interaction Inhibitor
FKBP51-Hsp90-IN-1 is a selective inhibitor targeting the FKBP51-Hsp90 protein-protein interaction, exhibiting an IC50 value of 0.1 μM against FKBP51. This compound is valuable for research into stress-related diseases, Alzheimer's disease, and various metabolic disorders, owing to its ability to modulate protein interactions critical for cellular stress responses and stability. Its specificity makes it a potent tool for elucidating the role of FKBP51 in disease mechanisms. -
FKBP51-Hsp90 Inhibitor
FKBP51-Hsp90-IN-2 is a selective inhibitor of the FKBP51-Hsp90 protein-protein interaction, demonstrating IC50 values of 0.4 µM for FKBP51 and 5 µM for FKBP52. This compound has been shown to enhance cellular energy metabolism and promote neurite growth. Its efficacy makes FKBP51-Hsp90-IN-2 a valuable tool in research focused on neurodegenerative diseases and cancer. -
Inflammatory Biomarker
8-Bromo-2'-deoxyguanosine is a halogenated DNA adduct associated with inflammation, serving as an early biomarker for oxidative tissue damage linked to inflammatory processes. Its formation precedes the generation of other oxidative and nitrative stress products and can be synthesized through the MPO-H2O2-Cl−-Br− system. This compound plays a critical role in detecting early DNA modifications using the monoclonal antibody mAb8B3, suitable for preclinical research. Additionally, its urinary levels are significantly elevated in various inflammatory disease models, making 8-Bromo-2'-deoxyguanosine valuable for investigations into inflammatory diseases, diabetes, hepatocellular carcinoma, and UV-B induced skin injuries. -
Anti-Inflammatory Agent
Vitisin A is a resveratrol tetramer with potent anti-inflammatory properties. It exerts its biological activity by inhibiting LPS-induced nitric oxide (NO) and inducible nitric oxide synthase (iNOS) production through the down-regulation of ERK1/2, p38, and NF-κB signaling pathways. Additionally, Vitisin A demonstrates antioxidative, anticancer, and neuroprotective effects while also inhibiting adipocyte differentiation. This compound is derived from the roots of Vitis vinifera and serves as a valuable reagent for research in inflammation and related diseases. -
Antagonist
Peptide E5 is an antagonist that targets the CXCR4/CXCL12 signaling axis. By blocking this interaction, Peptide E5 downregulates CXCR4 expression and inhibits the phosphorylation of key downstream proteins, Akt and Erk, leading to apoptosis in breast cancer cells. Additionally, Peptide E5 suppresses cellular migration and adhesion, as well as the recruitment of endothelial progenitor cells, thereby inhibiting tumor angiogenesis. This peptide is a valuable tool for research related to breast cancer and tumor microenvironment interactions. -
CXCR4 Antagonist
Peptide R analogue 10 is a potent CXCR4 antagonist, demonstrating enhanced antagonistic activity, specificity, and plasma stability compared to its predecessor, Peptide R. This compound effectively inhibits CXCL12-mediated cell migration, ERK phosphorylation, and CXCR4 internalization. Peptide R analogue 10 is valuable for research applications involving CXCR4 overexpression in models of leukemia and colon cancer. -
KRAS(Q61H) Inhibitor
RM-046 is a selective inhibitor targeting the KRAS(Q61H) mutant, functioning through the formation of a ternary complex with cyclophilin A. This compound non-covalently binds to activated KRASQ61H, obstructing effector binding and thereby inhibiting downstream signal transduction pathways. RM-046 has demonstrated efficacy in suppressing ERK phosphorylation, stalling cancer cell proliferation, and promoting anti-tumor activity, including tumor regression in preclinical xenograft studies. It serves as a valuable tool for investigating KRASQ61H-associated malignancies.
